sFlt-1 in Chronic Kidney Disease: Friend or Foe?

Int J Mol Sci. 2022 Nov 16;23(22):14187. doi: 10.3390/ijms232214187.

Abstract

Placental growth factor (PlGF) and its receptor, fms-like tyrosine kinase-1 (Flt-1), are important regulators involved in angiogenesis, atherogenesis, and inflammation. This review article focuses on the function of PlGF/Flt-1 signaling and its regulation by soluble Flt-1 (sFlt-1) in chronic kidney disease (CKD). Elevation of circulating sFlt-1 and downregulation of sFlt-1 in the vascular endothelium by uremic toxins and oxidative stress both exacerbate heart failure and atherosclerosis. Circulating sFlt-1 is inconsistent with sFlt-1 synthesis, because levels of matrix-bound sFlt-1 are much higher than those of circulating sFlt-1, as verified by a heparin loading test, and are drastically reduced in CKD.

Keywords: PlGF; cardiorenal connection; sFlt-1.

Publication types

  • Review

MeSH terms

  • Atherosclerosis / complications
  • Atherosclerosis / metabolism
  • Female
  • Humans
  • Oxidative Stress
  • Placenta Growth Factor / metabolism
  • Renal Insufficiency, Chronic* / genetics
  • Renal Insufficiency, Chronic* / metabolism
  • Vascular Endothelial Growth Factor Receptor-1* / genetics
  • Vascular Endothelial Growth Factor Receptor-1* / metabolism

Substances

  • Placenta Growth Factor
  • Vascular Endothelial Growth Factor Receptor-1